Zura Bio Limited (ZURA)
NASDAQ: ZURA
· Real-Time Price · USD
1.48
0.01 (0.68%)
At close: May 02, 2025, 12:48 PM
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
The company is based in San Diego, California.
Zura Bio Limited
| Country | United States |
| IPO Date | Mar 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Robert Lisicki |
Contact Details
Address: 4225 Executive Square San Diego, California United States | |
| Website | https://zurabio.com |
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855644 |
| CUSIP Number | n/a |
| ISIN Number | KYG9TY5A1016 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Lisicki | Chief Executive Officer & Director |
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Kimberly Ann Davis J.D. | Chief Operating Officer, Chief Legal Officer & Corporate Secretary |
| Verender S. Badial | Chief Financial Officer |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development |
| Dr. Someit Sidhu M.D. | Founder & Director |
| Theresa Lowry | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 4 | Filing |